If you have been reading about reverse-phase HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
| Property | Value | Notes |
|---|---|---|
| Detection wavelength | 214 nm | Peptide bond absorption; 280 nm is not useful. |
| Confirmatory method | Electrospray mass spectrometry | Verifies mass near 3108 Da. |
| Solution stability | Limited at room temperature | Aqueous solutions degrade faster than powder. |
| Recommended storage | -20 °C | For lyophilized powder; protect from moisture. |
| Purity criterion | ≥95% by RP-HPLC | Typical research-grade specification. |
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
=== Poisoning and detoxification === Diallyl disulfide is an efficient agent for detoxication of the cells. It significantly increases the production of the enzyme glutathione S-transferase (GST), which binds electrophilic toxins in the cell. Garlic therefore supports, for example, the detoxification function of liver cells in vitro and protects nerve cells from oxidative stress, also in vitro. The detoxification effect may prevent symptoms of inflammation. This was confirmed in a study on rats where prolonged administration of diallyl disulfide protected poisoning of their intestinal cells. This study also showed that certain side effects of high doses of garlic oil are not attributable to the diallyl disulfide. By supporting the detoxification activity in the liver, diallyl disulfide might offer liver protection during the chemotherapy, e.g. against cyanide detoxification.
The Lima Group has not issued any pronouncement since January 5 of this year, and that one does not even belong to the current management." No other country has mentioned the non-existence of the Lima Group.
Flowing-afterglow mass spectrometry (FA-MS), is an analytical chemistry technique for the sensitive detection of trace gases. Trace gas molecules are ionized by the production and flow of thermalized hydrated hydronium cluster ions in a plasma afterglow of helium or argon carrier gas along a flow tube following the introduction of a humid air sample. These ions react in multiple collisions with water molecules, their isotopic compositions reach equilibrium and the relative magnitudes of their isotopomers are measured by mass spectrometry.
=== Discontinuation === The British National Formulary recommends a gradual withdrawal when discontinuing antipsychotics to avoid acute withdrawal syndrome or rapid relapse. Symptoms of withdrawal commonly include nausea, vomiting, and loss of appetite. Other symptoms may include restlessness, increased sweating, and trouble sleeping. Less commonly, there may be a feeling of the world spinning, numbness, or muscle pains. Symptoms generally resolve after a short period of time. There is tentative evidence that discontinuation of antipsychotics can result in psychosis. It may also result in reoccurrence of the condition that is being treated. Rarely, tardive dyskinesia can occur when the medication is stopped.
=== Regulations === Because of the adverse effects of cadmium on the environment and human health, the supply and use of cadmium is restricted in Europe under the REACH Regulation. The EFSA Panel on Contaminants in the Food Chain specifies that 2.5 μg/kg body weight is a tolerable weekly intake for humans. The Joint FAO/WHO Expert Committee on Food Additives has declared 7 μg/kg body weight to be the provisional tolerable weekly intake level. The state of California requires a food label to carry a warning about potential exposure to cadmium on products such as cocoa powder. The European Commission has put in place the EU regulation (2019/1009) on fertilizing products (EU, 2019), adopted in June 2019 and fully applicable as of July 2022. It sets a Cd limit value in phosphate fertilizers to 60 mg kg−1 of P2O5. The U.S. Occupational Safety and Health Administration (OSHA) has set the permissible exposure limit (PEL) for cadmium at a time-weighted average (TWA) of 0.005 ppm. The National Institute for Occupational Safety and Health (NIOSH) has not set a recommended exposure limit (REL) and has designated cadmium as a known human carcinogen. The IDLH (immediately dangerous to life and health) level for cadmium is 9 mg/m3.
Sources: en.wikipedia.org
The sale allows TGI Fridays to repay its $23.9 million bankruptcy loan, with about $8 million in cash left over. On January 29, 2025, it was announced TGI Fridays UK's flagship restaurant in Leicester Square, London, had closed down. On January 30, 2025, it was reported that 30 more locations had closed, which left the chain with only around 100 locations remaining in the US. On February 3, 2025, it was announced that 19 of TGI Fridays' corporate-owned restaurants had been sold to two separate franchisees: three to Sugarloaf Hospitality and 16 to Yadav Enterprises, and that TGI Fridays had rejected the leases for six more restaurants. On 31 October 2025, it was announced that Sugarloaf TGIF Management had acquired TGI Friday's 49 UK restaurants from Calveton UK and Breal Capital as part of an international consolidation of the brand under Ray Blanchette. Sugarloaf is establishing a UK-led management team for the restaurants. However, less than three months later, on 14 January 2026, TGI Fridays closed 16 restaurants and went into administration for the second time in a year.
== History == The safety and efficacy of rusfertide were evaluated in the VERIFY trial, a multicenter, randomized, double-blind, placebo-controlled phase III study of 293 adults with polycythemia vera who required frequent phlebotomies despite ongoing standard-of-care therapy. Participants were randomized 1:1 to receive either rusfertide or placebo over 32 weeks. Mimrylo treatment started at 19 mg, administered subcutaneously (under the skin) once weekly, and was titrated to maintain hematocrit levels below 45%. Efficacy was measured by the proportion of participants who did not meet criteria for phlebotomy between weeks 20 and 32 of the study. Overall, 76.9% of participants on rusfertide required no phlebotomies during the 32-week period compared to 32.9% on placebo.
Prior to 1919 only atomic weights averaged over a very large number of atoms was available. In that year, Francis Aston built the first mass spectrograph, an improved form of a device built by J. J. Thomson to measure the deflection of positively charged atoms by electric and magnetic fields. Aston was then able to separate the isotopes of many light elements including neon, 20Ne and 22Ne. Aston discovered the isotopes matched William Prout's whole number rule: the mass of every isotope is a whole number multiple of hydrogen. Significantly, the one exception to this whole number rule was hydrogen itself, which had a mass value of 1.008. The excess mass was small, but well outside the limits of experimental uncertainty. Aston and others realized this difference was due to the binding energy of atoms. When a number of hydrogen atoms are bound into an atom, that atom's energy must be less than the sum of the energies of the separate hydrogen atoms. That lost energy, according to the mass-energy equivalence principle, means the atomic mass will be slightly less than the sum of the masses of its components. Aston's work on isotopes won him the 1922 Nobel Prize in Chemistry for the discovery of isotopes in a large number of non-radioactive elements, and for his enunciation of the whole number rule.
== General consequences == Point mutations that occur in non-coding sequences are most often without consequences, although there are exceptions. If the mutated base pair is in the promoter sequence of a gene, then the expression of the gene may change. Also, if the mutation occurs in the splicing site of an intron, then this may interfere with correct splicing of the transcribed pre-mRNA. By altering just one amino acid, the entire peptide may change, thereby changing the entire protein. The new protein is called a protein variant. If the original protein functions in cellular reproduction then this single point mutation can change the entire process of cellular reproduction for this organism. Point germline mutations can lead to beneficial as well as harmful traits or diseases. This leads to adaptations based on the environment where the organism lives. An advantageous mutation can create an advantage for that organism and lead to the trait's being passed down from generation to generation, improving and benefiting the entire population. The scientific theory of evolution is greatly dependent on point mutations in cells. The theory explains the diversity and history of living organisms on Earth. In relation to point mutations, it states that beneficial mutations allow the organism to thrive and reproduce, thereby passing its positively affected mutated genes on to the next generation. On the other hand, harmful mutations cause the organism to die or be less likely to reproduce in a phenomenon known as natural selection.
=== Post-2003 === Production ended on 2 October 2003 and the whole Familia line were replaced by the Mazda3 in the same month. The eighth generation Familia continued to be produced by Ford Lio Ho in Taiwan as the "Mazda Isamu Genki" until 2008 (sold as hatch and saloon and with little or no styling differences to the original 1998 production model). It was also badged as the "Ford Activa", which, unlike the Ford Laser, had no styling changes from the 323, except for the badges. In Southeast Asia, a version of the last Laser continued to be assembled in Indonesia, Malaysia, and the Philippines as the Ford Lynx. This generation remained in production in some South American countries (Ecuador, Colombia, and Venezuela), badged as the Mazda Allegro. Each Allegro keeps in the styling of the last generation 323/Protegé/Astina/Familia. In Colombia, production of the Mazda 323 continued until 2003, built by its local subsidiary, the Compañía Colombiana Automotriz. Chinese company FAW Haima Automobile Co., Ltd. produces a restyled version of the Familia/323 called Haima Family from 2003 to 2010. It is equipped with a 1.6 L petrol engine mated with a five-speed manual or a four-speed automatic gearbox. Another version called the Haima Happin went on sale from 2008 to 2012 model years with a facelift for 2011 and 2012 models. The Happin was equipped with a 1.3 L, 1.5 L, and 1.6 L engine options and a five-speed manual gearbox.
Sources: en.wikipedia.org
=== Appellate reversal === On October 24, 2011, the United States Court of Appeals for the Second Circuit ruled in favor of Banki and reversed the sanctions charges against him. Judge Keenan's court-ordered Banki's release 10 days later on November 2, 2011. The appellate court ruled that Judge John F. Keenan had erred at trial; in denying Banki's defense request to instruct the jury on the law that specifically exempts family money as an exception to the sanctions law, permitting such transfers without the need for a license. The final appellate court brief stated: "Banki's conviction [on the sanctions charges] cannot stand". Prosecutors reopened the case to pursue a retrial in February 2012. However, after a few months of delay and the assignment of a new judge, the case was closed criminally with no option for future civil or criminal prosecution. Rather than pay for the high cost of a second criminal defense trial, Banki agreed to relinquish $710k of his assets. In exchange, prosecutors agreed that Banki was not guilty of the sanctions charges without going through a second trial and that they would end pursuing the case further in criminal or civil courts. The case was permanently closed on July 24, 2012. In the final court hearing, Banki's prison record was cleared. During the hearing, Banki said he had lived through "the darkest hours" of his life while in prison. "I watched my life pass me by. Those days will never be replaced". Judge Engelmayer in clearing Banki's prison record called him a "talented man, even brilliant". The judge also stated: ". . .
After two years, the inquiry concluded with three principal findings and several recommendations, including required training for administrators, directors of nursing, and service organizations, improved screening processes and background checks for new hires, minimizing the use of agency nurses in long-term care homes, improved reporting processes for critical incidents, and changes to certain Ontario provincial regulations.
Nicotinamide N-methyltransferase (NNMT) is an enzyme that in humans is encoded by the NNMT gene. NNMT catalyzes the methylation of nicotinamide and similar compounds using the methyl donor S-adenosyl methionine (SAM-e) to produce S-adenosyl-L-homocysteine (SAH) and 1-methylnicotinamide.
== Sunderland's classification == In 1951, Sunderland expanded Seddon's classification to five degrees. The first two are the same as Seddon's. With each degree, the severity of the injury increases and has larger structural disruption and poorer prognosis. Sunderland's third-degree and fourth-degree are included within Seddon's axonotmensis. Sunderland's third-degree is nerve fiber interruption. This includes an endoneurium lesion with disruption of the axon and endoneurium, but an intact epineurium and perineurium. Recovery from a third-degree injury may require surgical intervention due to misdirected regeneration that is caused by endoneurial damage. In fourth-degree injury, only the epineurium remain intact, and a complete block to axonal regeneration could occur, requiring surgical repair. Sunderland's fifth-degree is included within Seddon's neurotmesis. Fifth-degree lesion is a complete transection of the nerve, including the epineurium. Recovery requires appropriate surgical treatment since there is no spontaneous recovery expected.
=== In war === Illicit use of the drug is thought to be a major factor in the success of the Boko Haram terrorist organization. When used at higher doses, the drug "can produce similar effects to heroin." One former member said, "whenever we took tramadol, nothing mattered to us anymore except what we were sent to do because it made us very high and very bold, it was impossible to go on a mission without taking it." Tramadol is also used as a coping mechanism in the Gaza Strip. In the 2020's Anti-balaka militias in the Central African Republic were reported to be in control of the Tramadol trade, providing it to fighters, workers in illegal goldmines and organising the sale on local markets. Researchers report the drug is brought by Dubai based company Shalina from India and China to the Democratic Republic of the Congo, from where it is smuggled into the Central African Republic.
Sources: en.wikipedia.org
Reverse-phase HPLC with ultraviolet detection at 214 nm is common. Mass spectrometry is used to confirm molecular identity and detect modifications. Immunoassays exist but may not distinguish the intact peptide from fragments.
The lyophilized powder is usually stored at -20 °C or below. Dissolved solutions are less stable and should be prepared fresh when possible. Freeze-thaw cycling can reduce integrity.
It lacks aromatic residues, so it does not absorb strongly at 280 nm. Its negative charge and hydrophilic nature can affect chromatographic retention. These properties require method development for reliable separation.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.